CHMP ‘negative trend vote’ for Exondys 51

Sarepta Therapeutics Inc. (NASDAQ:SRPT) said late Thursday in its 1Q18 earnings that EMA’s CHMP issued a “negative trend vote” for Exondys 51 eteplirsen, which is under EMA

Read the full 273 word article

User Sign In